论文部分内容阅读
目的:探讨参麦注射液辅助用于急性ST段抬高型心肌梗死溶栓治疗后对心肌损伤的保护作用。方法:选取在我院接受治疗的急性ST段抬高型心肌梗死(STEMI)患者120例,分为对照组和实验组各60例。对照组采用瑞通立溶栓,实验组在对照组治疗的基础上增加参麦注射液。观察两组冠脉再通情况;检查治疗前后左室射血分数(LVEF)和左心室舒张末期内径(LVEDD),记录再发心梗、再发心绞痛、恶性心律失常、泵衰竭、心源性死亡的发生情况;记录ST段回复情况及ST段恢复正常时间;观察肌酸激酶(CK)和肌酸激酶同工酶(CK-MB)峰值时间及恢复正常时间。结果:采用秩和检验,实验组临床疗效显著优于对照组(P<0.01);治疗后实验组左室射血分数(LVEF)高于对照组(P<0.05);两组冠脉再通率分别为78.33%和88.33%,实验组高于对照组,但差异无统计学意义;对照组不良心血管事件累积发生率为95%,高于实验组的63.33%(P<0.01);治疗后实验组ST段平均回落幅度多于对照组(P<0.01),ST段恢复正常短于对照组(P<0.01);治疗后实验组CK和CK-MB峰值时间及恢复正常时间均短于对照组(P<0.01)。结论:参麦注射液辅助用于急性ST段抬高型心肌梗死溶栓治疗后患者能改善患者心功能,减轻缺血再灌注损伤,改善心肌供血,保护心肌,减少不良心血管事件的发生。
Objective: To investigate the protective effect of Shenmai injection on myocardial injury after thrombolysis in acute ST-segment elevation myocardial infarction. Methods: A total of 120 acute ST-elevation myocardial infarction (STEMI) patients treated in our hospital were selected and divided into control group and experimental group of 60 cases each. The control group using Ruitong legislation thrombolysis, the experimental group in the control group based on the increase of Shenmai injection. Left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) were observed before and after treatment. Recurrent myocardial infarction, recurrent angina pectoris, malignant arrhythmia, pump failure, cardiogenic The occurrence of death was recorded. The recovery of ST segment and the recovery time of ST segment were recorded. The peak time of creatine kinase (CK) and creatine kinase (CK-MB) and the recovery time were observed. Results: The rank sum test showed that the clinical efficacy of the experimental group was significantly better than that of the control group (P <0.01). The left ventricular ejection fraction (LVEF) of the experimental group was significantly higher than that of the control group (P <0.05) The rates of adverse cardiovascular events in the control group were 95%, which were higher than those in the experimental group (63.33%, P <0.01). The treatment rate was 78.33% and 88.33% respectively. The experimental group was higher than the control group, but the difference was not statistically significant The mean drop-off amplitude of ST segment in post-experiment group was more than that in control group (P <0.01), and ST segment recovery was shorter than that in control group (P <0.01). The peak time and recovery time of CK and CK- Control group (P <0.01). Conclusion: Shenmai injection can improve cardiac function, relieve ischemia-reperfusion injury, improve myocardial blood supply, protect myocardium and reduce the incidence of adverse cardiovascular events after thrombolysis in patients with acute ST-elevation myocardial infarction.